NextCure, Inc. Income Statement
NXTC|3 years of annual SEC 10-K data (FY2019-FY2021)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 3 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Revenue
$22M
FY2021
Gross Profit
N/A
FY2021
Operating Income
-$41M
FY2021
Net Income
-$37M
FY2021
NextCure, Inc. reported $22M in revenue and $37M in net loss for FY2021. Revenue has grown at a 87.8% compound annual rate over the past 2 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score NaN (distress zone, below 1.23 threshold)
- Currently unprofitable: Net income is negative
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2021 | FY2020 | FY2019 |
|---|---|---|---|
| Revenue | $22.4M | $6.3M | $6.3M |
| SG&A Expense | $17.0M | $9.6M | $3.4M |
| R&D Expense | $46.6M | $34.2M | $19.8M |
| Operating Income | -$41.2M | -$37.5M | -$23.2M |
| Interest Expense | - | $209.0K | $25.0K |
| Net Income | -$36.6M | -$33.7M | -$22.8M |
| EPS (Basic) | -$1.33 | - | - |
| EPS (Diluted) | -$1.33 | -$2.15 | -$16.64 |
| Shares Outstanding | 15.6M | 15.6M | 1.4M |
| Operating Margin | -184.2% | -590.5% | -365.5% |
| Profit Margin | -163.6% | -531.5% | -359.2% |